Expert Review of Anticancer Therapy最新文献_第8页

Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis. 胃癌中 TIMP1 表达的临床病理和预后意义：系统综述和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-24 DOI: 10.1080/14737140.2024.2408278

Mingcan Zheng, Puxu Wang, Yuhang Wang, Zirui Jia, Jiacheng Gao, Xiaodong Tan, Hailong Chen, Guo Zu

{"title":"Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis.","authors":"Mingcan Zheng, Puxu Wang, Yuhang Wang, Zirui Jia, Jiacheng Gao, Xiaodong Tan, Hailong Chen, Guo Zu","doi":"10.1080/14737140.2024.2408278","DOIUrl":"10.1080/14737140.2024.2408278","url":null,"abstract":"Background: The research on the associations between tissue inhibitors of metalloproteinase-1 (TIMP1) expression and the clinicopathological characteristics and prognosis of patients with gastric cancer (GC) have resulted in contradictory findings. Exploring the associations between TIMP1 and clinicopathological parameters and the prognosis of GC patients is essential.Methods: We searched the literature in the databases according to the inclusion and exclusion criteria. Hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the relationships between TIMP1 expression and the clinicopathological parameters and prognosis of GC patients.Results: Nine studies with 1,200 GC patients were included. Our results indicated that TIMP1 expression was not related to sex, age, TNM stage, depth of invasion, lymph node metastasis, or tumor size in GC patients. However, TIMP1 expression was associated with the differentiation of GC. Furthermore, TIMP1 expression was associated with poor prognosis in GC patients.Conclusion: TIMP1 expression was related to tumor differentiation and poor prognosis but not sex, age, TNM stage, depth of invasion, lymph node metastasis or tumor size.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1169-1176"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interventions to reduce the risk of side-effects of cancer treatments in childhood. 降低儿童癌症治疗副作用风险的干预措施。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-09 DOI: 10.1080/14737140.2024.2411255

Bob Phillips, Jess Morgan, Ruth Walker, Claudia Heggie, Salah Ali

{"title":"Interventions to reduce the risk of side-effects of cancer treatments in childhood.","authors":"Bob Phillips, Jess Morgan, Ruth Walker, Claudia Heggie, Salah Ali","doi":"10.1080/14737140.2024.2411255","DOIUrl":"10.1080/14737140.2024.2411255","url":null,"abstract":"Introduction: Childhood cancers as a group affect around 1 in 500 children but each individual diagnosis is a rare disease. While research largely focuses on improving cure rates, the management of side effects of treatment are high priority for clinicians, families and children and young people.Areas covered: The prevention and efficient management of infectious complications, oral mucositis, nausea and vomiting and graft-vs-host disease illustrated with examples of implementation research, translation of engineering to care, advances in statistical methodologies, and traditional bench-to-patient development. The reviews draw from existing systematic reviews and well conducted clinical practice guidelines.Expert opinion: The four areas are driven from patient and family priorities. Some of the problems outlined are ready for proven interventions, others require us to develop new technologies. Advancement needs us to make the best use of new methods of applied health research and clinical trial methodologies. Some of the greatest challenges may be those we're not fully aware of, as new therapies move from their use in adult oncological practice into children. This will need us to continue our collaborative, multi-professional, multi-disciplinary and eclectic approach.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1117-1129"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. 骨髓增生异常综合征/肿瘤（MDS）的靶向疗法：当前形势与未来方向。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-17 DOI: 10.1080/14737140.2024.2414071

Aram Bidikian, Jan P Bewersdorf, Rory M Shallis, Ted M Getz, Jessica M Stempel, Tariq Kewan, Maximilian Stahl, Amer M Zeidan

{"title":"Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions.","authors":"Aram Bidikian, Jan P Bewersdorf, Rory M Shallis, Ted M Getz, Jessica M Stempel, Tariq Kewan, Maximilian Stahl, Amer M Zeidan","doi":"10.1080/14737140.2024.2414071","DOIUrl":"10.1080/14737140.2024.2414071","url":null,"abstract":"Introduction: Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of hematologic malignancies that are stratified into high-risk (HR-MDS) and low-risk (LR-MDS) categories. Until recently, LR-MDS has been typically managed by supportive measures and erythropoiesis-stimulating agents (ESAs); whereas management of HR-MDS typically included hypomethylating agents and allogeneic hematopoietic stem cell transplant. However, the limited rates and durations of response observed with these interventions prompted the search for targeted therapies to improve the outcomes among patients with MDS.Areas covered: Here, we review the current landscape of targeted therapies in MDS. These include pyruvate kinase and hypoxia-inducible factor (HIF) activators; TGF-beta, telomerase, BCL2 and isocitrate dehydrogenase (IDH) inhibitors; as well as novel approaches targeting inflammation, pyroptosis, immune evasion, and RNA splicing machinery.Expert opinion: This review highlights the progress and challenges in MDS treatment. Despite some promising results, many therapies remain in early development or have faced setbacks, emphasizing the need for a more comprehensive understanding of the disease's pathobiology. Continued research into targeted therapies, homogenous clinical trial designs, as well as increased incorporation of molecular prognostic tools and artificial intelligence into trial design are essential for developing effective treatments for MDS and improving patient outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1131-1146"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Future investigative directions for novel therapeutic targets in head and neck cancer. 头颈癌新型治疗靶点的未来研究方向。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-16 DOI: 10.1080/14737140.2024.2417038

Jacqueline P Nguyen, Liam C Woerner, Daniel E Johnson, Jennifer R Grandis

引用次数: 0

Treatment of skin cancers in solid organ transplant recipients: current status and future perspectives. 实体器官移植受者皮肤癌的治疗：现状与未来展望。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-24 DOI: 10.1080/14737140.2024.2408280

Emilie Ducroux, Jean Kanitakis

引用次数: 0

Infrared radiation for cancer hyperthermia: the light to brighten up oncology. 用于癌症热疗的红外线辐射：照亮肿瘤学的明灯。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.1080/14737140.2024.2416063

Mengna Ye, Dashan Yin, Yufei Wu, Hua Miao, Zhibing Wu, Pengyuan Liu

{"title":"Infrared radiation for cancer hyperthermia: the light to brighten up oncology.","authors":"Mengna Ye, Dashan Yin, Yufei Wu, Hua Miao, Zhibing Wu, Pengyuan Liu","doi":"10.1080/14737140.2024.2416063","DOIUrl":"10.1080/14737140.2024.2416063","url":null,"abstract":"Introduction: Cancer constitutes the greatest public health threat to humans, as its incidence and mortality rates continue to increase worldwide. With the development of medical physics, more practitioners focus on the direct and indirect anti-tumor effects of physical factors. Infrared radiation (INR) is currently the most rapidly developing physical therapy method for tumors and has become a favored target for many oncologists and researchers owing to its advantages of high efficiency, low toxicity, and strong feasibility.Areas covered: This work provides a comprehensive collection of the latest information on INR anti-tumor research, drawing from public medical databases (PubMed, Web of Science, Embase, and Clinical Trials) from the last 10 years (2014 to 2024), and encompassing both basic and clinical research in oncology and physics. This article reviews the application of INR in tumor hyperthermia, summarizes and analyzes the practical value of INR for tumor treatment, and discusses future development trends to provide valuable assistance for the subsequent development of oncology.Expert opinion: Currently, INR has continuously accumulated excellent data in the field of tumor hyperthermia, bringing practical survival benefits to patients with cancer, and playing an important role in basic and clinical cancer research.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1147-1160"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic accuracy of magnetic resonance diffusion tensor imaging in distinguishing pseudoprogression from glioma recurrence: a systematic review and meta-analysis. 磁共振弥散张量成像在区分假性进展和胶质瘤复发方面的诊断准确性：系统回顾和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-14 DOI: 10.1080/14737140.2024.2415404

Xiaoyi Wu, Mai Zhang, Quan Jiang, Mingxi Li, Yuankui Wu

{"title":"Diagnostic accuracy of magnetic resonance diffusion tensor imaging in distinguishing pseudoprogression from glioma recurrence: a systematic review and meta-analysis.","authors":"Xiaoyi Wu, Mai Zhang, Quan Jiang, Mingxi Li, Yuankui Wu","doi":"10.1080/14737140.2024.2415404","DOIUrl":"10.1080/14737140.2024.2415404","url":null,"abstract":"Purpose: To evaluate the diagnostic accuracy of diffusion tensor imaging (DTI)-derived metrics mean diffusivity (MD) and fractional anisotropy (FA) in differentiating glioma recurrence from pseudoprogression.Methods: The Cochrane Library, Scopus, PubMed, and the Web of Science were systematically searched. Study selection and data extraction were done by two investigators independently. The quality assessment of diagnostic accuracy studies was applied to evaluate the quality of the included studies. Combined sensitivity (SEN) and specificity (SPE) and the area under the summary receiver operating characteristic curve (SROC) with the 95% confidence interval (CI) were calculated.Results: Seven high-quality studies involving 246 patients were included. Quantitative synthesis of studies showed that the pooled SEN and SPE for MD were 0.81 (95% CI 0.70-0.88) and 0.82 (95% CI 0.70-0.90), respectively, and the value of the area under the SROC curve was 0.88 (95% CI 0.85-0.91). The pooled SEN and SPE for FA were 0.74 (95% CI 0.65-0.82) and 0.79 (95% CI 0.66-0.88), respectively, and the value of the area under the SROC curve was 0.84 (95% CI 0.80-0.87).Conclusions: This meta-analysis showed that both MD and FA have a high diagnostic accuracy in differentiating glioma recurrence from pseudoprogression.Registration: PROSPERO protocol: CRD42024501146.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1177-1185"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. 曲妥珠单抗-德鲁司坦治疗晚期 HER2 低乳腺癌患者的疗效。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2023-09-12 DOI: 10.1080/14737140.2023.2171993

Ilana Schlam, Sara M Tolaney, Paolo Tarantino

{"title":"The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer.","authors":"Ilana Schlam, Sara M Tolaney, Paolo Tarantino","doi":"10.1080/14737140.2023.2171993","DOIUrl":"10.1080/14737140.2023.2171993","url":null,"abstract":"Introduction: Until recently, the available human receptor epidermal growth factor 2 (HER2) targeted agents were ineffective for treating patients with HER2-low expressing breast cancer (defined as immunohistochemical expression of 1+ or 2+ without amplification). The development of novel and potent HER2-directed antibody-drug conjugates, affective at treating HER2-low expressing breast cancers, have changed the way we think about HER2-low expression and expanded the treatment options for many patients with advanced disease.Areas covered: In this review, we summarize the current management of HER2-low breast cancer and commonly encountered challenges such as treatment sequencing and toxicity management.Expert opinion: trastuzumab deruxtecan (T-DXd) is a treatment option for patients with advanced, HER2-low breast cancer, irrespective of the hormone receptor status. The current optimal place in treatment algorithms is after the first line of chemotherapy, both in HR-positive and triple-negative breast cancer; however, other agents are available in this setting and risks and benefits for each should be considered in shared decision making. Up to 10-15% of patients receiving T-DXd develop interstitial lung disease. Patient and clinician education are key to safely implement T-DXd in clinical practice.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1059-1066"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10208624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The diagnostic value of CYFRA 21-1 in oral squamous cell carcinoma: a meta-analysis. CYFRA 21-1 在口腔鳞状细胞癌中的诊断价值：一项荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-23 DOI: 10.1080/14737140.2024.2405225

Yuting Liang, Zhenke Yi, Jiajin Li, Jufeng Ye

{"title":"The diagnostic value of CYFRA 21-1 in oral squamous cell carcinoma: a meta-analysis.","authors":"Yuting Liang, Zhenke Yi, Jiajin Li, Jufeng Ye","doi":"10.1080/14737140.2024.2405225","DOIUrl":"10.1080/14737140.2024.2405225","url":null,"abstract":"Background: Previous studies have revealed the importance of CYFRA 21-1 in the diagnosis of oral squamous cell cancer (OSCC). However, the results are inconsistent. This meta-analysis is to evaluate CYFRA 21-1's efficacy in distinguishing OSCC.Methods: Systematic searches of Web of Science, PubMed, and CNKI (1996-2024) were conducted following the Preferred Reporting ltems for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.Results: Analysis of 693 patients and 548 controls yielded combined sensitivity (SEN) of 0.71 (95% CI: 0.68, 0.75), specificity (SPE) of 0.88 (95% CI: 0.85, 0.90), and area under the curve (AUC) of 0.927. Subgroup analysis showed higher SEN (0.88), SPE (0.93), and AUC (0.962) in saliva versus serum. Enzyme-linked immunosorbent assay (ELISA) demonstrated superior performance over electrochemiluminescent immunoassay (ECLIA) (AUC: 0.968 vs. 0.868).Conclusion: CYFRA 21-1 is effective in OSCC diagnosis, with ELISA showing better sensitivity. Saliva emerges as a promising diagnostic medium compared to serum.Registration: PROSPERO CRD42024566835.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1161-1168"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for the prevention or reversal of PARP inhibitor resistance. 预防或逆转 PARP 抑制剂耐药性的策略。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-10-01 Epub Date: 2024-08-20 DOI: 10.1080/14737140.2024.2393251

Zahi Mitri, Shaun M Goodyear, Gordon Mills

{"title":"Strategies for the prevention or reversal of PARP inhibitor resistance.","authors":"Zahi Mitri, Shaun M Goodyear, Gordon Mills","doi":"10.1080/14737140.2024.2393251","DOIUrl":"10.1080/14737140.2024.2393251","url":null,"abstract":"Introduction: Advances in our understanding of tumor biology shed light on hallmarks of cancer development and progression that include dysregulated DNA damage repair (DDR) machinery. Leveraging the underlying tumor genomic instability and tumor-specific defects in DDR, Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) induced DNA damage emerges as a novel non-chemotherapy therapeutic opportunity. PARPis are currently approved in multiple tumor types, with the largest benefit seen in tumors with homologous recombination repair (HRR) deficiency, including germline and somatic mutations in BRCA1/2 genes (BRCA) and other pathway members such as PALB2 and Rad51c.Areas covered: This review article summarizes the current approval landscape and known and proposed mechanisms of resistance to PARPi. Further, therapeutic strategies to overcome PARPi resistance are discussed, including ongoing clinical trials.Expert opinion: PARPi have proven to be a safe and effective therapy and represents a cornerstone treatment across multiple solid tumor types. Elucidating innate and acquired mechanisms of resistance, coupled with the emergence of novel therapeutic options to capitalize on the activity of PARPi and prevent or reverse the acquisition of resistance, provides an opportunity to further expand the role of PARPi in cancer therapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"959-975"},"PeriodicalIF":2.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0